June 2018 – KaNDy Therapeutics

Posted 25th June 2018

Mary Kerr CEO NeRRe Therapeutics and Managing Director KaNDY Therapeutics will be presenting a case study on the “Demerger of NT-814 to KaNDY Therapeutics, Business Model Innovation and Value Creation; 7TH LSX CEO FORUM , Wednesday 27th June 2018, CMS, Cannon Place, 78 Cannon St, London EC4N 6AF

Posted 21st June 2018

KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls

Stevenage, UK, 21 June 2018 – KaNDy Therapeutics, a UK clinical-stage biotech company, today announces the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls for both KaNDy [...]

By FDM Digital

In Company News

Posted 7th June 2018

KaNDy Therapeutics announces positive clinical data with lead candidate NT-814 for the treatment of symptoms of the menopause

~Phase Ib/IIa data showed rapid and highly significant reductions in the frequency and severity of hot flashes and the number of night time awakenings~ ~NT-814 is being developed to provide a [...]